Broadening the Therapeutic Armamentarium Against Plaque Psoriasis
Podcast 3
Post-Test/Evaluation

Questions marked with a * are required

22%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Choosing initial psoriasis treatment and continuing or altering subsequent treatment should

always include which of the following?

Outlining that psoriasis is ultimately a curable disease

Focusing on preventing future exacerbations over medication side effects

Continuing the same treatment when there’s major breakthrough activity

Making shared decisions together with the patient to help maximize patient engagement and adherence

Which of the following is a recently-approved TYK2 inhibitor for psoriasis that was approved

based on strong PASI 75 and PASI 90 data versus apremilast?

Upadacitinib

Deucravacitinib

Bimekizumab

Tofacitinib

A 28-year-old woman presents to her dermatologist with moderate psoriasis (7% body surface

area) on her neck, scalp, arms, and shoulders. When discussing treatment for this patient, which

of the following would be an indicator that a TYK2 inhibitor might be preferred over other

systemic therapies?

She doesn’t want to take medication every day

She would prefer an oral agent over injection

She has mild disease

She has severe hepatic impairment

Powered by QuestionPro

Loading...